| PRECLINICAL | evidence | Interplay of childhood metabolic dysfunction-associated steatotic liver disease and obesity in the development of youth-onset type 2 diabetes. | Semaglutide | — | 2026-03-09 |
| PRECLINICAL | evidence | Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor? | Semaglutide | Glycemic control | 2026-03-05 |
| PRECLINICAL | evidence | Females are protected from semaglutide-induced muscle loss in ob/ob mice. | Semaglutide | — | 2026-03-05 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. | Semaglutide | Glycemic control | 2026-03-04 |
| PRECLINICAL | evidence | Combined Treatment of Type 2 Diabetes and Hypothyroidism: Impact of Oral Semaglutide and Levothyroxine on Cardiometabolic and Thyroid Parameters: A 6-Month Comparative Study. | Semaglutide | — | 2026-03-04 |
| PRECLINICAL | evidence | Microbes, mood, and metabolism/obesity: Pharmacological insights into the gut-obesity-depression triad. | Semaglutide | Mood & anxiety | 2026-03-03 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity. | Semaglutide | Glycemic control | 2026-03-03 |
| PRECLINICAL | evidence | GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023. | Semaglutide | — | 2026-03-02 |
| PRECLINICAL | evidence | The Glucagon-like Peptide-1 Receptor Agonist Era and Its Influence on Body-Contouring Referrals After Weight Loss in Appalachia. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | Semaglutide-Associated Acute Pancreatitis in a Patient With Type 2 Diabetes Mellitus: A Case Report. | Ozempic | — | 2026-03-01 |
| PRECLINICAL | evidence | Heart failure with preserved ejection fraction: updated diagnostic and therapeutic strategies. SEMI consensus document. | semaglutida | Lipid & cardiovascular markers | 2026-03-01 |
| PRECLINICAL | evidence | THR-beta Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Semaglutide for Managing Antipsychotic-associated Weight Gain: A Systematic Review and Meta-analysis. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | The ethics of Wegovy: promoting autonomy in pediatric care. | Ozempic | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Semaglutide-induced transient intestinal ischemia: A case report. | Ozempic | — | 2026-03-01 |
| PRECLINICAL | evidence | Pharma-cology 101: Educating future prescribers on drug reps, dead drugs, and the hidden scripts of pharmaceutical industry relationships. | Ozempic | — | 2026-03-01 |
| PRECLINICAL | evidence | Semaglutide and weight loss in obese patients with and without type 2 diabetes. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance. | Ozempic | — | 2026-03-01 |
| PRECLINICAL | evidence | Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. | Semaglutide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists. | Wegovy | — | 2026-03-01 |
| PRECLINICAL | evidence | Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population. | Wegovy | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | [Obesity: novel pharmacological treatments]. | Semaglutide | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Semaglutide Hype or Hope: Evidence-based Review in Diabesity. | Ozempic | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon-Like Peptide 1 Agonist: A Case Report. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy. | Semaglutide | — | 2026-03-01 |
| PRECLINICAL | evidence | Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study). | Wegovy | — | 2026-03-01 |
| PRECLINICAL | evidence | 15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist-Induced Weight Loss. | Semaglutide | — | 2026-02-28 |
| PRECLINICAL | evidence | [Semaglutide-induced acute-on-chronic liver failure: A case report and literature review]. | Semaglutide | Glycemic control | 2026-02-28 |
| PRECLINICAL | evidence | Semaglutide ameliorates coronary microembolization-induced injury by suppressing apoptosis and inflammation via the HMGB1/RAGE/NF-kappaB p65 pathway. | Semaglutide | — | 2026-02-28 |
| PRECLINICAL | evidence | Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm. | Semaglutide | — | 2026-02-28 |
| PRECLINICAL | evidence | The Ethics of Ozempic and Wegovy. | Ozempic | Glycemic control | 2026-02-27 |
| PRECLINICAL | evidence | Weighty matters: Ozempic, autonomy and the ethics of health reform. | Ozempic | Weight & fat loss | 2026-02-27 |
| PRECLINICAL | evidence | Reply: The ethics of Ozempic and Wegovy. | Ozempic | — | 2026-02-27 |
| PRECLINICAL | evidence | New weight loss pill outperforms oral semaglutide for diabetes patients, study reports. | Semaglutide | — | 2026-02-27 |
| PRECLINICAL | evidence | Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions. | Semaglutide | — | 2026-02-27 |
| PRECLINICAL | evidence | Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis. | Semaglutide | — | 2026-02-26 |
| PRECLINICAL | evidence | Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis. | Semaglutide | — | 2026-02-25 |
| PRECLINICAL | evidence | Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis. | Semaglutide | — | 2026-02-24 |
| PRECLINICAL | evidence | Weight loss drug waste: what happens to the Ozempic pens? | Ozempic | — | 2026-02-23 |
| PRECLINICAL | evidence | Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. | Semaglutide | — | 2026-02-21 |
| PRECLINICAL | evidence | Secondary Prevention of Cardiovascular Events in Patients with Overweight/Obesity in Routine Clinical Practice. | Semaglutide | — | 2026-02-20 |
| PRECLINICAL | evidence | Plasma Proteomic Analysis of APOE epsilon4 Homozygotes Identifies Preclinical Alzheimer's Disease Alterations Potentially Treatable with Semaglutide. | Semaglutide | — | 2026-02-17 |
| PRECLINICAL | evidence | In brief: Removal of suicidality warning from GLP-1 Agonists for weight management. | Wegovy | — | 2026-02-16 |